Targeted radio-immuno-chemotherapy against liver metastases of gastric cancer using radio-labeled chimeric monoclonal antibody and chimeric antibody-drug conjugates.

点击翻译按钮获取中文摘要

1)Preparation of radio-labeled chimeric monoclonal antibodyChimeric monoclonal antibody chA7 was labeled with 131-I, and purified.2)In vitro antitumor effects of 131-I labeled chA7In vitro antitumor effects of 131-I labeled chA7 against human gastric cancer cell lines were investigated. The effects showed greater than that of chA7 alone.3)Production of murine liver metastases model using human gastric cancer cell linesA murine liver metastases model of gastric cancer was tried to produce using human gastric cancer cell lines, such as MKN1, MKN45 and KATOIII, injected into subserosa of spleen. A suitable model was not succeeded to produce.4)Acute toxicity of 131-I labeled chA7 for miceAcute toxicity of 131-I labeled chA7 for mice was checked. No severe toxicity was noted under 55.5MBq/a mouse of 131-I chA7.5)Biodistribution of 131-I chA7 in mice bearing liver metastases of gastric cancerBiodistribution of 131-I chA7 in mice bearing liver metastases of gastric cancer was not investigated because murine liver metastases model could not be made. So biodistribution of 131-I chA7 in mice bearing subcutaneous gastric cancer tumor. 131-I chA7 accumulated most in the tumor 2 hour after injection.6)In vivo tumoricidal effects of 131-I chA7 against gastric cancerNude mice bearing human gastric cancer tumor were received 7.4MBq/ a mouse or 14.8MBq/ a mouse of 131-I chA7 2 weeks after tumor inoculation. No significnant effect was noted in both group.